

PERFORMANCE OF A METHOD FOR QUANTIFYING PROGRANULIN AS A TARGET ENGAGEMENT BIOMARKER FOR AZP2006 IN PROGRESSIVE SUPRANUCLEAR PALSY.

Christine Bain¹, Cécilia Estrella², Aurélien Blondel², Renaud Jasnowski¹, Audrey Pabiou¹, Philippe Verwaerde², Aurélie Chene¹, Noëlle Callizot², Cendrine Josson¹


1. KCAS Bio www.kcasbio.com | + Phone number | 60F Rockefeller Av., Bioserra II – 69008 – Lyon – France
2. Alzprotect | www.alzprotect.com | + 33(0)359537043 | 85 Rue Nelson Mandela, 59120 – Loos, France



Progranulin and Progressive Supranuclear Palsy

Progranulin (PGRN)

- Involved in neuroinflammation, neurite branching, neuron survival & lysosomal functions
- Low PGRN levels linked to neurodegeneration



AZP2006


- Promotes neuroprotection in neurodegenerative diseases models.
- Interacts with prosaposin (PSAP) and promotes the stabilization of PGRN.
- KCAS Bio:** quantified PGRN levels in PSP patients from a Phase IIa clinical trial sponsored by Alzprotect
- Context of Use** = PGRN levels in plasma and CSF as a target engagement marker

Working range of Adipogen PGRN ELISA kit is consistent with expected levels in CSF & plasma


A. PGRN ELISA kits

PGRN ELISA Kit	Parallelism	Selectivity	Sensitivity (plasma)	Sensitivity (CSF)
Biotechne	✓	✓	✓	✗
Adipogen	✓	✓	✓	✓

B. Endogenous PGRN linearly measured



C. No interfering proteins in CSF or plasma



– MRD in CSF = 4 ; plasma = 200

ACC : 70-130% | CV: <25%

Pre-study performance

Clinical study launch

LOQs & Long-term storage stability estimated in-study

A. Working range

Calibration curves (CC) from 6 in-study analytical runs


Plasma: 50 – 800 ng/mL*

CSF: 1 – 16 ng/mL

* Lowest and highest calibrators meeting ACC & P (CV) criteria (values adjusted for MRD)

B. Stability at -80°C

Demonstrated up to 52 weeks




ACC : 70-130% | CV: <25% | CC: >75%


In-study performance

Impact of AZP2006 treatment in PSP patients

A. AZP2006 increases PGRN levels in plasma



B. AZP2006 prevents PGRN decrease in CSF



ACC : 70 – 130% (CC) | CV: <25% (in-study samples)

In-study sample analysis

Conclusion: Quantification of PGRN by a method, qualified according to its context-of-use, generates reliable results, establishing PGRN as a target engagement biomarker for AZP2006 in PSP.

